Selenium in the Prevention of Cancer
Recruitment status was Active, not recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. Selenium may be effective in preventing cancer. It is not yet known which dose of selenium may be most effective in preventing cancer.
PURPOSE: Randomized pilot study to determine the effectiveness of selenium in preventing cancer in healthy people.
| Condition | Intervention |
|---|---|
|
Unspecified Adult Solid Tumor, Protocol Specific |
Dietary Supplement: selenium |
| Study Type: | Interventional |
| Study Design: | Primary Purpose: Prevention |
| Official Title: | Prevention Of Cancer By Intervention With Selenium |
| Study Start Date: | October 1999 |
OBJECTIVES: I. Determine whether daily supplementation with selenium significantly reduces total cancer incidence and site-specific cancer incidence in the general population. II. Determine whether this regimen has a beneficial effect on mood.
OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Participants are stratified according to age (60-64 vs 65-69 vs 70-74). Participants are randomized to one of four arms. Arm I: Participants receive oral placebo once daily. Arm II: Participants receive low-dose oral selenium once daily. Arm III: Participants receive moderate-dose oral selenium once daily. Arm IV: Participants receive high-dose oral selenium once daily. Treatment in all arms continues for up to 2 years in the absence of unacceptable side effects or diagnosis of cancer.
PROJECTED ACCRUAL: A total of 510 patients (170 per stratum) will be accrued for this study within 9-12 months.
Eligibility| Ages Eligible for Study: | 60 Years to 74 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS: Healthy men and women No prior diagnosis of cancer except non-melanoma skin cancer
PATIENT CHARACTERISTICS: Age: 60 to 74 Performance status: SWOG 0-1 Life expectancy: Not specified Hematopoietic: Not specified Hepatic: No active liver disease No known abnormal liver function Renal: No active kidney disease No known abnormal kidney function Other: HIV negative No diminished mental capacity that would preclude study
PRIOR CONCURRENT THERAPY: No other concurrent selenium supplements (50 ug/day or more)
Contacts and Locations| United Kingdom | |
| Hammersmith Hospital | |
| London, England, United Kingdom, W12 ONN | |
| United Kingdom Coordinating Committee on Cancer Research-ABC | |
| Sutton, England, United Kingdom, SM2 5NG | |
| University Of Surrey | |
| Guildford, United Kingdom, GU2 5XH | |
| Study Chair: | Margaret Rayman, DPhil | University of Surrey |
More Information
Additional Information:
No publications provided
| ClinicalTrials.gov Identifier: | NCT00022165 History of Changes |
| Other Study ID Numbers: | CDR0000068791, SURREY-UK-PRECISE, EU-20113 |
| Study First Received: | August 10, 2001 |
| Last Updated: | February 6, 2009 |
| Health Authority: | United States: Federal Government |
Keywords provided by National Cancer Institute (NCI):
|
unspecified adult solid tumor, protocol specific |
Additional relevant MeSH terms:
|
Selenium Trace Elements Micronutrients Growth Substances Physiological Effects of Drugs |
Pharmacologic Actions Antioxidants Molecular Mechanisms of Pharmacological Action Protective Agents |
ClinicalTrials.gov processed this record on May 19, 2013